Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea

Won Suk Choi, Ji Yun Noh, Jacob Lee, Jun Yong Choi, Jin Soo Lee, Moo Soo Kim, Hee Soo Kim, Joon Bang, Nathalie Lavis, Woo Joo Kim

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)


    VaxigripTetra® (Sanofi Pasteur, Lyon, France) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) containing two B-lineage strains approved in the European Union and Taiwan in 2016 for individuals ≥ 3 years of age. Here, we describe an observer-blind, randomized, controlled, multicenter trial study evaluating the immunogenicity and safety of the Northern Hemisphere 2015–2016 formulations of IIV4 and the licensed split-virion trivalent inactivated influenza vaccine (IIV3) in the Republic of Korea ( no. NCT02550197). The study included 300 Korean adults 18–60 years of age randomized 2:1 to receive a single injection of IIV4 or IIV3. For each of the four vaccine strains in IIV4, 21 days after vaccination, geometric mean post-/pre-vaccination ratios of hemagglutination inhibition titers were ≥ 3.97. Seroconversion/significant increases rates were ≥ 40% for all but the A/H1N1 strain, for which the rate was 39.7%. Results were similar for the three strains in IIV3. For the additional B-lineage strain not in IIV3 (Victoria), hemagglutination inhibition antibody titers were higher for IIV4 than for IIV3. Solicited reactions and adverse events were similar between IIV4 and IIV3, and no serious adverse events or new safety signals were detected. These results confirm the robust immunogenicity and acceptable safety of IIV4 in adults 18–60 years of age and show that including a second B-lineage strain should provide broader protection against B-strain influenza without affecting vaccine safety or the immunogenicity of other three vaccine strains.

    Original languageEnglish
    Pages (from-to)587-592
    Number of pages6
    JournalHuman Vaccines and Immunotherapeutics
    Issue number3
    Publication statusPublished - 2018 Mar 4


    • Republic of Korea
    • adults
    • inactivated influenza vaccine
    • quadrivalent influenza vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Pharmacology


    Dive into the research topics of 'Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea'. Together they form a unique fingerprint.

    Cite this